Enhertu NHS approval

NHS approves Enhertu for HER2-low breast cancer in England

Thousands of women in England with HER2-low advanced breast cancer will get access to the life-extending drug Enhertu on the NHS after ministers reached a pricing deal. The treatment, which can give patients an extra seven months on average, had initially been rejected on cost grounds. Enhertu has been available in Scotland for more than two years.